By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


OXiGENE, Inc. 

230 Third Avenue

Waltham  Massachusetts  02451  U.S.A.
Phone: 781-547-5900 Fax: 781-547-6800



Company News
OXiGENE (OXGN) Reports Third Quarter 2015 Financial Results 11/11/2015 8:29:03 AM
OXiGENE (OXGN) Announces Positive Initial Data From Phase Ib Study Of CA4P In Combination With Pazopanib In Patients With Advanced Recurrent Ovarian Cancer 11/6/2015 6:56:01 AM
OXiGENE (OXGN) Announces Initiation Of Phase Ib/II Clinical Trial Of Oxi4503 In Acute Myeloid Leukemia 10/22/2015 7:34:39 AM
OXiGENE (OXGN) To Present At The 14th Annual BIO Investor Forum 10/19/2015 7:46:05 AM
OXiGENE (OXGN) Announces Interim Phase II Data For Lead Clinical Candidate CA4P (Fosbretabulin) In Neuroendocrine Tumors 10/19/2015 7:27:37 AM
OXiGENE (OXGN) Announces Plans To Advance CA4P (Fosbretabulin) In Two Late-Stage Clinical Trials 9/30/2015 7:09:09 AM
OXiGENE (OXGN) Reports Second Quarter 2015 Financial Results 8/5/2015 7:43:48 AM
OXiGENE (OXGN) To Host Second Quarter Financial Results Conference Call And Webcast 7/28/2015 8:27:10 AM
OXiGENE (OXGN) Appoints Matthew M. Loar As Chief Financial Officer 7/21/2015 7:24:06 AM
OXiGENE (OXGN) Receives Guidance From FDA Supporting Phase III Trial Of Fosbretabulin/Bevacizumab Combination In Platinum-Resistant Ovarian Cancer 6/1/2015 8:10:27 AM